Evercore ISI Upgrades TESARO (TSRO) to Outperform

Evercore ISI upgraded shares of TESARO (NASDAQ:TSRO) from an in-line rating to an outperform rating in a research report report published on Thursday morning, Marketbeat reports. They currently have $88.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on the stock. BidaskClub lowered shares of TESARO from a sell rating to a strong sell rating in a research report on Saturday, February 10th. Piper Jaffray Companies reaffirmed a hold rating and set a $65.00 price objective on shares of TESARO in a research report on Thursday, January 18th. Credit Suisse Group reaffirmed an outperform rating and set a $150.00 price objective (down previously from $190.00) on shares of TESARO in a research report on Thursday, January 18th. Morgan Stanley cut their price objective on shares of TESARO from $165.00 to $156.00 and set an overweight rating for the company in a research report on Tuesday, January 16th. Finally, HC Wainwright reaffirmed a buy rating and set a $158.00 price objective on shares of TESARO in a research report on Friday, January 12th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $148.60.

TESARO (NASDAQ:TSRO) opened at $60.89 on Thursday. The firm has a market cap of $3,372.22, a price-to-earnings ratio of -7.21 and a beta of 1.25. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34. TESARO has a 52-week low of $55.02 and a 52-week high of $190.74.

In related news, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the transaction, the senior vice president now owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 40.50% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Exane Derivatives raised its position in TESARO by 137.1% in the fourth quarter. Exane Derivatives now owns 1,942 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 1,123 shares in the last quarter. Toronto Dominion Bank raised its position in TESARO by 244.6% in the third quarter. Toronto Dominion Bank now owns 1,592 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,130 shares in the last quarter. Bourgeon Capital Management LLC acquired a new position in TESARO in the fourth quarter worth about $211,000. Fox Run Management L.L.C. acquired a new position in TESARO in the fourth quarter worth about $218,000. Finally, Commonwealth Equity Services Inc acquired a new position in TESARO in the third quarter worth about $222,000.

COPYRIGHT VIOLATION NOTICE: This report was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/02/23/evercore-isi-upgrades-tesaro-tsro-to-outperform.html.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply